Tvardi Therapeutics (LTS:0HTC) Interest Expense: £0.00 Mil (TTM As of Mar. 2026)


What is Tvardi Therapeutics Interest Expense?

Tvardi Therapeutics LTS:0HTC 12 Interest Expense is £0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tvardi Therapeutics's interest expense for the three months ended in Mar. 2026 was £ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was £0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Tvardi Therapeutics's Operating Income for the three months ended in Mar. 2026 was £ -5.29 Mil. Tvardi Therapeutics's Interest Expense for the three months ended in Mar. 2026 was £ 0.00 Mil. GuruFocus does not calculate Tvardi Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tvardi Therapeutics  (LTS:0HTC) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tvardi Therapeutics's Interest Expense for the three months ended in Mar. 2026 was £0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was £-5.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was £0.04 Mil.

Tvardi Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Tvardi Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Tvardi Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Tvardi Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Interest Expense Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tvardi Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of £0.00 Mil mean?
Tvardi Therapeutics (LTS:0HTC) has a Interest Expense of £0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Interest Expense too high?
Tvardi Therapeutics' current Interest Expense is £0.00 Mil. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Interest Expense compare to HOWL and TPST?
Tvardi Therapeutics' Interest Expense of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Interest Expense is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Interest Expense of £0.00 Mil. The current Interest Expense is £0.00 Mil. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Interest Expense is £0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.